46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)

March 30 - April 3, 2011, Berlin, Germany

Back EASL 2011

EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine

76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011. alt

Read more:

EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug

Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL. alt

Read more:

Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment

The REALIZE study showed that adding telaprevir to standard hepatitis C therapy increased sustained response rates for people with previous unsuccessful treatment attempts, researchers reported this week at EASL 2011.

Read more:

EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status

The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.

Read more: